Cyclooxygenase‐2−765G&gt;C functional promoter polymorphism and its association with oral squamous cell carcinoma

Addala, Lakshmi; Sadhnani, Muralidhar; Kumar, Chennaboina Kalyan; Kumar, Amit; Chakravarthy, Pentapati Kalyana; Vasala, Anjaneyulu; Jamil, Kaiser

doi:10.1111/j.2041-1626.2011.00104.x

Cited by 5 publications

(3 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, this was in contrast to another study, in which the GG genotype was more frequent in controls than in OSCC patients (94.66% vs. 73.3%), and thus, could be protective against OSCC. Moreover, the study found that both the GC and the CC genotypes were associated with a significantly increased risk of OSCC [105]. Nonetheless, another two studies found no evidence for the role of −765G>C polymorphisms in the risk of developing OSCC [106,107].…”

Section: Cox-2-765g>cmentioning

confidence: 84%

Role of Cyclooxygenase-2 in Head and Neck Tumorigenesis

Frejborg

Salo

Salem

2020

IJMS

View full text Add to dashboard Cite

The cyclooxygenase-2 (COX-2) is a potent enzyme that converts arachidonic acid to prostaglandins (PG), including PGE2, a key mediator of inflammation and angiogenesis. Importantly, COX-2 is activated in response to inflammatory stimuli, where it is also believed to promote the development and progression of head and neck cancers (HNC). COX-2 can mediate its protumorigenic effect through various mechanisms, such as inducing cell proliferation, inhibition of apoptosis, and suppressing the host’s immune response. Furthermore, COX-2 can induce the production of vascular endothelial growth factors, hence, promoting angiogenesis. Indeed, the ability of COX-2 inhibitors to selectively restrict the proliferation of tumor cells and mediating apoptosis provides promising therapeutic targets for cancer patients. Thus, in this comprehensive review, we summarized the reported differential expression patterns of COX-2 in different stages of head and neck carcinogenesis—from potentially premalignant lesions to invasive carcinomas. Furthermore, we examined the available meta-analysis evidence for COX-2 role in the carcinogenesis of HNC. Finally, further understanding of the biological processes of COX-2 and its role in orchestrating cell proliferation, apoptosis, and angiogenesis may give therapeutically beneficial insight to develop the management plan of HNC patients and improve their clinical outcomes.

show abstract

Section: Cox-2-765g>cmentioning

confidence: 84%

Role of Cyclooxygenase-2 in Head and Neck Tumorigenesis

Frejborg

Salo

Salem

2020

IJMS

View full text Add to dashboard Cite

show abstract

“…Of them, 5 case–control studies involving 1564 cases and 2346 controls focused on COX-2 rs689466 polymorphism [ 28 , 30 , 31 , 33 , 34 ], 4 studies involving 1259 cases and 2097 controls on COX-2 rs5275 polymorphism [ 27 , 31 , 33 , 34 ], and 5 studies involving 1229 cases and 1164 controls on COX-2 rs20417 polymorphism [ 28 – 32 ]. One study did not satisfy the HWE for COX-2 rs5275 polymorphism [ 31 ] 1 for COX-2 rs20417 polymorphism [ 32 ]. The main characteristics are shown in Table 1 and Table 2 .…”

Section: Resultsmentioning

confidence: 99%

COX-2 rs689466, rs5275, and rs20417 polymorphisms and risk of head and neck squamous cell carcinoma: a meta-analysis of adjusted and unadjusted data

Wen

Kwong

et al. 2016

BMC Cancer

View full text Add to dashboard Cite

BackgroundNumerous case–control studies have been performed to investigate the association between three cyclooxygenase-2 (COX-2) polymorphisms (rs20417 (−765G > C), rs689466 (−1195G > A), and rs5275 (8473 T > C)) and the risk of head and neck squamous cell carcinoma (HNSCC). However, the results were inconsistent. Therefore, we conducted this meta-analysis to investigate the association.MethodsWe searched in PubMed, Embase, and Web of Science up to January 20, 2015 (last updated on May 12, 2016). Two independent reviewers extracted the data. Odds ratios (ORs) with their 95 % confidence intervals (CIs) were used to assess the association. All statistical analyses were performed using the Review Manager (RevMan) 5.2 software.ResultsFinally 8 case–control studies were included in this meta-analysis. For unadjusted data, an association with increased risk was observed in three genetic models in COX-2 rs689466 polymorphism; however, COX-2 rs5275 and rs20417 polymorphisms were not related to HNSCC risk in this study. The pooled results from adjusted data all revealed non-significant association between these three polymorphisms and risk of HNSCC. We also found a similar result in the subgroup analyses, based on both unadjusted data and adjusted data.ConclusionCurrent results suggest that COX-2 rs689466, rs5275, and rs20417 polymorphisms are not associated with HNSCC. Further large and well-designed studies are necessary to validate this association.

show abstract

“…All of the seven previous studies on the association between genetic polymorphisms of the PG pathway and HNC risk have only included PTGS2 (COX‐2) (Chiang et al , ; Lin et al , ; Peters et al , ; Jeong et al , ; Mittal et al , ; Lakshmi et al , ; Niu et al , ). In the present study, we conducted a comprehensive investigation of genetic polymorphisms of six genes ( PGDS, PTGDS, PTGES, PTGIS, PTGS1, and PTGS2 ) in the PG pathway and examined their association with HNC risk.…”

Section: Introductionmentioning

confidence: 99%

Genetic polymorphisms in the prostaglandin pathway genes and risk of head and neck cancer

et al. 2014

View full text Add to dashboard Cite

show abstract

Cyclooxygenase‐2−765G>C functional promoter polymorphism and its association with oral squamous cell carcinoma

Abstract: This study highlights the genetic variant that might play a role in mediating susceptibility to oral squamous cell carcinoma in this population.

Cited by 5 publications

References 19 publications

Role of Cyclooxygenase-2 in Head and Neck Tumorigenesis

Role of Cyclooxygenase-2 in Head and Neck Tumorigenesis

COX-2 rs689466, rs5275, and rs20417 polymorphisms and risk of head and neck squamous cell carcinoma: a meta-analysis of adjusted and unadjusted data

Genetic polymorphisms in the prostaglandin pathway genes and risk of head and neck cancer

Contact Info

Product

Resources

About